Cramer 5-marker panel for ovarian cancer
|QA State:||Under Review|
The PLCO phase III specimens (test half) revealed marker panels produced only marginal improvement over CA 125 alone and, in some case, worse performance. Besides searching for new markers, some ways to improve detection might include: 1) Add epidemiologic variables, and 2) Add in prior markers values.
There are no datasets associated with this biomarker.